Overview

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with rituximab and lenalidomide in the treatment of relapsed and refractory diffuse large B-cell lymphoma (DLBCL).

Phase:

Phase 2

Details

Lead Sponsor:

Jianfeng Zhou

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Lenalidomide
Mitoxantrone
Rituximab